# A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

> **NCT06868485** · PHASE2 · RECRUITING · sponsor: **Wayshine Biopharm, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** WSD0922-FU Tablets, Dose level A
- **DRUG:** WSD0922-FU Tablets, Dose level B

## Key facts

- **NCT ID:** NCT06868485
- **Lead sponsor:** Wayshine Biopharm, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-18
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06868485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06868485, "A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06868485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*